As the panel discussion concludes, Peter Salgo, MD; Jeffrey D. Dunn, PharmD, MBA; Yehuda Handelsman, MD, FACP, FACE, FNLA; Maria Lopes, MD, MS; and Kari Uusinarkaus, MD, FAAFP, FNLA, share their final insights about managed care models and clinical and economic outcomes in diabetes and obesity.
Dr Dunn says that he expects challenges to accompany changes in drug formularies, and notes that all stakeholders involved in a patient’s care need to understand the importance of risk stratification, preventive measures, integrative care, and pharmacist-centric medication therapy management.
Dr Handelsman adds that society needs to focus on preventive measures and their long-term benefits.
Dr Lopes and Dr Uusinarkaus explain that there is no one-size-fits-all approach to addressing the diabetes and obesity epidemics. The panelists conclude that innovative population-based solutions that place an emphasis on prevention need to be developed by society, government, and the various stakeholders in the healthcare field.
The Biden administration recently launched the Global Health Security Strategy, a new effort to combat the spread of infectious diseases; lawmakers zeroed in on the risks of massive consolidation in health care during the first congressional hearing on the Change Healthcare hack; the FDA recently announced the recall of a pair of heart devices linked to numerous deaths and injuries.
Read More
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen